Thymosin Alpha-1

Mechanism of action

Thymosin alpha-1 (Tα1) is a 28-amino-acid N-terminally acetylated peptide (sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) originally isolated from bovine thymic Fraction 5 by Allan Goldstein's laboratory at the George Washington University in 1977, subsequently identified as an endogenous peptide produced by thymic epithelial cells through post-translational processing of the larger 113-amino-acid prothymosin alpha precursor. The synthetic recombinant peptide is identical to the endogenous form; the pharmaceutical product is manufactured by solid-phase peptide synthesis rather than biological source, avoiding the porcine/bovine biological-source complications of some other historical thymic-peptide preparations. The molecular mechanism of Tα1 involves engagement with the innate and adaptive immune systems at multiple levels. The principal characterised receptor mechanism involves Toll-like receptor 2 (TLR2) and TLR9 on dendritic cells and macrophages, with subsequent activation of NF-κB signalling and downstream cytokine expression modulation. Tα1 promotes dendritic cell maturation, enhances antigen presentation, and drives Th1-polarised T-cell responses through IL-12 production and STAT4 signalling. On T-cells directly, Tα1 promotes maturation from CD3+/CD4-/CD8- double-negative thymocytes to mature CD4+ and CD8+ subsets, with additional effects on peripheral T-cell function including enhanced IL-2 responsiveness and improved response to antigenic stimulation. The immune-modulating pharmacology is context-dependent — Tα1 has been characterised as a 'reset' rather than a purely stimulatory or purely suppressive compound. In immunosuppressed conditions (chronic viral hepatitis, HIV, cancer chemotherapy), Tα1 enhances immune function. In hyperinflammatory conditions (sepsis, severe COVID-19), Tα1 has been studied for its capacity to restore immune balance rather than further amplify inflammation. This bidirectional immune-modulatory profile distinguishes Tα1 from single-directional immunomodulators like corticosteroids or specific cytokine antagonists. Downstream physiological effects reflect the immune-modulatory pharmacology. In chronic hepatitis B and C (the principal clinical indications in registered jurisdictions), Tα1 enhances viral clearance rates when combined with standard antiviral therapy through improved T-cell-mediated hepatocyte clearance. In hepatocellular carcinoma, Tα1 has been studied as an adjuvant to loco-regional treatment (transarterial chemoembolisation) with signals of improved outcomes. In HIV, Tα1 has been studied as an adjuvant to antiretroviral therapy with modest signals of improved CD4 T-cell recovery. During the COVID-19 pandemic, Tα1 was extensively studied in Chinese and Italian clinical practice for severe COVID-19 with mixed results across multiple observational and RCT studies. An important mechanistic distinction is that Tα1 is unrelated to Thymosin Beta-4 (Tβ4) despite the similar naming. Both were isolated from the same historical bovine thymic Fraction 5 preparation but are structurally, mechanistically, and pharmacologically distinct compounds. Tα1 is an immune-modulator (28 amino acids, N-terminally acetylated, TLR2/TLR9 pathway); Tβ4 is an actin-binding tissue-repair peptide (43 amino acids, no acetylation, G-actin sequestration through the LKKTETQ motif). The nomenclature is historical (both named for their appearance in the Fraction 5 preparation) and can be misleading — see the thymosin-alpha1-vs-thymosin-beta4 comparison for the detailed differentiation.

Thymosin alpha-1 was among the first thymic peptides isolated (Goldstein et al., PNAS 1977) and remains the most clinically-developed thymic peptide immunomodulator, with regulatory approval in approximately 35 countries and a substantial clinical safety record spanning 30+ years — yet notably absent from FDA, MHRA, and EMA regulatory frameworks despite the extensive international clinical use.

— Notable finding

Research history

Thymosin alpha-1 was first isolated by Allan Goldstein and colleagues at the George Washington University from bovine thymic Fraction 5 in 1977 — the same laboratory and preparation that yielded thymosin beta-4 identified concurrently. The two peptides were named for their electrophoretic behaviour in the Fraction 5 preparation (α for the first migrating fraction, β for the second) and the naming has persisted despite the two peptides being structurally and mechanistically distinct. Following the initial isolation, Tα1 was extensively characterised biochemically and mechanistically through the 1980s and 1990s. Clinical development began in the 1980s with early studies in hepatitis B and immunodeficiency contexts. SciClone Pharmaceuticals licensed the compound for development, and Zadaxin (the trade name for thymalfasin, the synthetic acetylated form) received first regulatory approvals in Italy, Kuwait, and Peru in the early 1990s. Progressive registration across additional jurisdictions has produced current approval in approximately 35 countries for indications including chronic hepatitis B, chronic hepatitis C, hepatocellular carcinoma (adjuvant to loco-regional treatment), HIV/AIDS, immune dysfunction associated with cancer chemotherapy, and vaccination adjuvant applications. Notable regulatory absences include the United States (FDA approval has not been pursued to completion — SciClone's US development was halted after early trials), the United Kingdom (MHRA authorisation has not been sought), and other major Western European jurisdictions (EMA authorisation has similarly not been pursued). The regulatory geography reflects both commercial-development decisions by SciClone and the challenges of aligning multi-indication immune-modulator pharmacology with Western regulatory expectations for tight indication-specific efficacy demonstration. During the COVID-19 pandemic, Tα1 became a subject of substantial clinical research interest in China and Italy as an immune-modulator for severe COVID-19. Multiple RCTs and observational studies produced mixed results, with some suggesting mortality benefit in specific patient subgroups and others showing no significant benefit. The COVID-19 evidence base has not translated to new regulatory approvals but has expanded the clinical-research familiarity with the compound. In the UK in 2025-2026, Tα1 (thymalfasin/Zadaxin) is not available as a licensed medicine. Specialist access through the unlicensed-medicines 'specials' route is theoretically possible for individual patients through importation from countries where it is registered; UK research-grade material is available from research-chemical suppliers.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Thymosin alpha-1 has one of the strongest peptide-drug clinical safety records among compounds on this site, accumulated through 30+ years of Zadaxin clinical use across 35+ countries in chronic hepatitis, HIV, cancer adjuvant, and other immune-modulation indications. The adverse-event profile is remarkably favourable: mild-and-transient adverse effects predominate, with injection-site reactions (mild erythema, transient nodules) being the most common; occasional mild flu-like symptoms during initial dosing; no clinically significant changes in routine haematology, biochemistry, or vital signs at therapeutic doses. The endogenous nature of thymosin alpha-1 — the synthetic peptide is identical to the naturally occurring thymic peptide — is the principal safety feature. Immunogenicity risk is minimal because the peptide sequence is self-derived; anti-Tα1 antibodies have not been documented as a clinically significant issue in the extensive clinical experience. The bidirectional immune-modulatory profile (restorative rather than one-directionally stimulatory or suppressive) reduces the risk of pathological immune activation that would complicate long-term immune-modulator use. Serious adverse events specifically attributable to Tα1 have been rare across the clinical-trial and post-marketing experience. Autoimmune activation (theoretically possible with any immune-modulator) has not been a documented clinical issue at therapeutic doses. Malignancy signals have not emerged from long-term chronic hepatitis use. Chronic hepatitis use in patients with existing hepatocellular carcinoma or high HCC risk has produced mixed signals in some observational analyses — with the interpretation depending on whether Tα1 is considered to promote immune-mediated tumour surveillance (beneficial) or to complicate tumour immune-evasion dynamics (theoretical concern). The registered adjuvant HCC indications reflect the balance of evidence favouring net benefit. The safety profile has been consistently favourable across the varying clinical-trial and clinical-use contexts. Tα1 is one of the peptide-drug class most-suitable for chronic long-term immune-modulation from a pure safety standpoint.

UK regulatory status

Thymosin alpha-1 (thymalfasin, Zadaxin) is NOT authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no UK marketing authorisation. It is registered as a prescription medicine in approximately 35 countries — including Italy in Europe — for indications spanning chronic hepatitis B/C, HCC adjuvant, HIV, and immune dysfunction. The UK, US, and other major Western jurisdictions have not authorised it. It is not a controlled substance under the Misuse of Drugs Act 1971. Research-grade material for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration of Tα1 to humans outside an authorised UK clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — registration in Italy or other countries does not authorise UK supply or use. Specialist UK access through the unlicensed-medicines 'specials' route (Regulation 167 of the Human Medicines Regulations 2012) is theoretically possible for individual patients with hepatitis or other Zadaxin-indicated conditions, typically through importation from European (Italian) pharmacies. In practice this route is rarely pursued given the strong effectiveness of contemporary direct-acting antiviral therapies for hepatitis C (which have largely displaced Tα1's principal use case) and the reasonable effectiveness of contemporary hepatitis B management. Tα1 is not currently on the WADA Prohibited List. Its immune-modulatory mechanism does not fall within any current WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, Tα1 work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

Frequently asked questions